REGN earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E 15.31. Updated 2026-07-23.
Regeneron Pharmaceuticals (REGN) Research Hub
Regeneron Pharmaceuticals (REGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 781.49 USD (-3.24%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 15.31, market cap 67.05B. This hub links to the full technical, earnings and options research available for REGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 781.49 USD (-3.24%) |
| 52-week range | 594.9 USD – 859.34 USD |
| Trend regime | Range |
| 14-day RSI | 49.3 (Neutral) |
| Trailing P/E | 15.31 |
| Market cap | 67.05B |
| Dividend yield | 0.56% |
| Next earnings | 2026-07-30 |
Available research for REGN
Covered Call on REGN: how it works, illustrative setup around the real 781.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on REGN: how it works, illustrative setup around the real 781.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on REGN: how it works, illustrative setup around the real 781.49 USD price, max profit/loss, breakeven and when to use it. Educational.
REGN technical analysis: range, last 781.49 USD, RSI 49.3, 52w range 594.9 USD–859.34 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is REGN in?
Regeneron Pharmaceuticals (REGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is REGN in an uptrend or downtrend?
As of 2026-09-11, REGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is REGN's trailing P/E ratio?
REGN's trailing P/E is 15.31, with a market cap of 67.05B. See the earnings research page for full valuation detail.
When does REGN next report earnings?
REGN is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 10.21 USD.